AU2003303543A1 - Agonist antibody against heteroreceptor - Google Patents

Agonist antibody against heteroreceptor

Info

Publication number
AU2003303543A1
AU2003303543A1 AU2003303543A AU2003303543A AU2003303543A1 AU 2003303543 A1 AU2003303543 A1 AU 2003303543A1 AU 2003303543 A AU2003303543 A AU 2003303543A AU 2003303543 A AU2003303543 A AU 2003303543A AU 2003303543 A1 AU2003303543 A1 AU 2003303543A1
Authority
AU
Australia
Prior art keywords
heteroreceptor
antibody against
agonist antibody
agonist
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003303543A
Inventor
Shinya Ishii
Keiko Kasutani
Tetsuo Kojima
Osamu Natori
Chiaki Senoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2003303543A1 publication Critical patent/AU2003303543A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003303543A 2002-12-26 2003-11-28 Agonist antibody against heteroreceptor Abandoned AU2003303543A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-377078 2002-12-26
JP2002377078 2002-12-26
PCT/JP2003/015230 WO2004060919A1 (en) 2002-12-26 2003-11-28 Agonist antibody against heteroreceptor

Publications (1)

Publication Number Publication Date
AU2003303543A1 true AU2003303543A1 (en) 2004-07-29

Family

ID=32708285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003303543A Abandoned AU2003303543A1 (en) 2002-12-26 2003-11-28 Agonist antibody against heteroreceptor

Country Status (3)

Country Link
JP (1) JPWO2004060919A1 (en)
AU (1) AU2003303543A1 (en)
WO (1) WO2004060919A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CL2008001071A1 (en) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Method to obtain penta-specific antibody against human il-8 / cxcl8, gro-alpha / cxcl1, gro-beta / cxcl2), gro-gamma / cxcl3 and ena-78 / cxcl5; penta-specific antibody; production process of the same; vector, hybridoma or cella that comprises it; pharmaceutical composition; use to treat copd, other diseases.
PE20090481A1 (en) 2007-07-16 2009-05-18 Genentech Inc ANTI-CD79B ANTIBODIES AND HUMANIZED IMMUNOCONJUGATES AND METHODS OF USE
RS52305B (en) 2007-07-16 2012-12-31 Genentech Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
SI2202245T1 (en) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
ES2587392T3 (en) 2008-01-31 2016-10-24 Genentech, Inc. Anti-CD79b and immunoconjugate antibodies and methods of use
CN105859889B (en) 2010-11-17 2020-01-07 中外制药株式会社 Multispecific antigen-binding molecules having a function replacing the function of factor VIII
BR112016006197B1 (en) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY
EP3940065A1 (en) 2013-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Method for producing antigen-binding molecule using modified helper phage
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
TWI700300B (en) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII)
TWI701435B (en) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 Method to determine the reactivity of FVIII
WO2016159213A1 (en) 2015-04-01 2016-10-06 中外製薬株式会社 Method for producing polypeptide hetero-oligomer
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
EP3509637A4 (en) 2016-09-06 2020-05-27 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
KR102063341B1 (en) * 2018-12-31 2020-01-07 다이노나(주) Antibody specifically binding to ICAM-1 and use thereof

Also Published As

Publication number Publication date
WO2004060919A1 (en) 2004-07-22
JPWO2004060919A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
AU2003289047A1 (en) Needle-insertion device
AU2003237647A1 (en) Lid-positioning device
AU2003281272A1 (en) Fireblocking device
AU2003233780A1 (en) Novel glucagon antagonists/inverse agonists
AU2003225126A1 (en) Inter-language translation device
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
AU2003293034A1 (en) Trans-thermoelectric device
AU2003303543A1 (en) Agonist antibody against heteroreceptor
AU2003245720A1 (en) Electroptic device
AU2003296164A1 (en) Connection device
AU2003256991A1 (en) Sample holder
AU2003268457A1 (en) Biomap analysis
AU2001246934A1 (en) Agonist antibodies
AU2003289154A1 (en) Analyzing device
AU2003235351A1 (en) Thickness measuring device
AU2003254589A1 (en) Connecting device
AU2003247851A1 (en) Camera-attachable device
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003246290A1 (en) Box-assembling device
AU2003270351A1 (en) Anesthetic-state determining
AU2003264142A1 (en) Connection device
AU2003252230A1 (en) Measuring device
AU2003212767A1 (en) Connection device
AU2003242918A1 (en) Module-testing device
AU2003288100A1 (en) Measuring device

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase